HSCI, a network of the nation’s top stem cell and regenerative medicine researchers, gathers to exchange ideas and forge new collaborations to advance biomedical research.
HSCI investigators have developed a better picture of why a recently discovered therapy for graft-versus-host disease (GVHD) is more effective than anything currently available to patients.
In 2011, human clinical trials showed that immune system signaling molecule interleukin 2 (IL-2) both improved...